Adrina Kocharian

Adrina Kocharian

Auto-generated profile, based on publicly available information

Adrina Kocharian

Laboratory of Behavioral and Genomic Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2015 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
Anna RadkeAnna Radke
Anna Radke
NJNicholas J. Jury
Nicholas J. Jury
AKAdrina Kocharian
Adrina Kocharian
CMCatherine A. Marcinkiewcz
Catherine A. Marcinkiewcz
ELEmily G. Lowery‐Gionta
Emily G. Lowery‐Gionta
AHAndrew Holmes
Andrew Holmes

24 February 2022 in Science
Verified
Journal Article
Closed access
BTBrian H. Trieu
Brian H. Trieu
BRBailey C. Remmers
Bailey C. Remmers
CTCarlee Toddes
Carlee Toddes
DBDieter D. Brandner
Dieter D. Brandner
ELEmilia M. Lefevre
Emilia M. Lefevre
PRPatrick Rothwell
Patrick Rothwell
Angiotensin-converting enzyme (ACE) regulates blood pressure by cleaving angiotensin I to produce angiotensin II. In the brain, ACE is especially abundant in striatal tissue, but the function of ACE in striatal circuits remains poorly understood. We found that ACE degrades an unconventional enkephalin heptapeptide, Met-enkephalin-Arg-Phe, in the nucleus accumbens of mice. ACE inhibition enhanced µ-opioid receptor activation by Met-enkephalin-Arg-Phe, causing a cell type–specific long-term depression of glutamate release onto medium spiny projection neurons expressing the Drd1 dopamine receptor. Systemic ACE inhibition was not intrinsically rewarding, but it led to a decrease in conditioned place preference caused by fentanyl administration and an enhancement of reciprocal social interaction. Our results raise the enticing prospect that central ACE inhibition can boost endogenous opioid signaling for clinical benefit while mitigating the risk of addiction.

10 May 2016 in eLife
Verified
Journal Article
Open access
JGJoyonna Carrie Gamble-George
Joyonna Carrie Gamble-George
RBRita Baldi
Rita Baldi
LHLindsay Halladay
Lindsay Halladay
AKAdrina Kocharian
Adrina Kocharian
NHNolan Hartley
Nolan Hartley
SPSachin Patel
Sachin Patel
Mood and anxiety disorders are the most prevalent psychiatric conditions and are exacerbated by stress. Recent studies have suggested cyclooxygenase-2 (COX-2) inhibition could represent a novel treatment approach or augmentation strategy for affective disorders including anxiety disorders and major depression. We show that traditional COX-2 inhibitors and a newly developed substrate-selective COX-2 inhibitor (SSCI) reduce a variety of stress-induced behavioral pathologies in mice. We found that these behavioral effects were associated with a dampening of neuronal excitability in the basolateral amygdala (BLA) ex vivo and in vivo, and were mediated by small-conductance calcium-activated potassium (SK) channel and CB1 cannabinoid receptor activation. Taken together, these data provide further support for the potential utility of SSCIs, as well as traditional COX-2 inhibitors, as novel treatment approaches for stress-related psychiatric disorders.

15 September 2018 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
Anna RadkeAnna Radke
Anna Radke
AKAdrina Kocharian
Adrina Kocharian
DCDan P. Covey
Dan P. Covey
DLDavid M. Lovinger
David M. Lovinger
JCJoseph F. Cheer
Joseph F. Cheer
AHAndrew Holmes
Andrew Holmes

21 September 2012 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
YMYohei Mineharu
Yohei Mineharu
AMAkm Ghulam Muhammad
Akm Ghulam Muhammad
KYKader Yagiz
Kader Yagiz
MCMarianela Candolfi
Marianela Candolfi
KKKurt M. Kroeger
Kurt M. Kroeger
MCMaria G. Castro
Maria G. Castro

1 February 2017 in Alcohol
Verified
Journal Article
Closed access
LHLindsay R. Halladay
Lindsay R. Halladay
AKAdrina Kocharian
Adrina Kocharian
AHAndrew Holmes
Andrew Holmes